HAEMATO AG

HAEMATO PHARM GmbH

HAEMATO PHARM GmbH specializes in the manufacture and sale of generics and EU original medicines. With its product portfolio, the company focuses on five major therapeutic areas: HIV / AIDS, Neurology, Oncology, Rheumatology and Urology.

HAEMATO MED GmbH

HAEMATO MED GmbH is an innovative healthcare company specializing in the development and commercialization of pharmaceutical, medical and medical devices for aesthetic surgery and cosmetic dermatology.

HAEMATO AG

HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.

News

We inform you about the current business development of HAEMATO AG and about our investor relations activities.

Q1 2020 RESULTS

by HAEMATO AG | May 31, 2021 | Investor News

HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350% to EUR 2.4 million and revenues by 22% to EUR 73.9 million. Berlin, 31.05.2021 - HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core...

HAEMATO AG proposes dividend payment

by HAEMATO AG | May 4, 2021 | Ad-Hoc Announcement

Ad hoc of HAEMATO AG pursuant to Art. 17 MAR:The Supervisory Board of HAEMATO AG approved the Executive Board's proposal for the appropriation of profits at today's balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of...

According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million

by HAEMATO AG | Apr 21, 2021 | Investor News

Corporate News of HAEMATO AG: According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million. In the 2020 financial year, HAEMATO AG,...

Click here for more news

Publications

Get an overview of the current status and development of HAEMATO AG. Here you will find information on the current status of the Group and on developments in recent years.

Read the Reports